First Author [Reference No.] | Country | Enrolment period | Study* | Analysis | No. of patients | Age, years, mean | Gender,% male |
---|---|---|---|---|---|---|---|
Peg-IFN | Peg-IFN | Peg-IFN | |||||
α-2a/α-2b | α-2a/α-2b | α-2a/α-2b | |||||
Yenice [16] | Turkey | No information | RCT, unblinded | Per protocol | 37/37 | 48.2 and 50.9^ | 35.1/27 |
50.8 and 50.85§ | |||||||
Di Bisceglie [17] | USA | No information | RCT, unblinded | Intention-to-treat | 189/191 | 46.9/48.4 | 64/71 |
Escudero [18] | Spain | May 2001 to December 2006 | Controlled | Intention-to-treat | 59/58 | 45.8/45.1 | 66.1/60.3 |
McHutchison [19] | USA | March 2004 to June 2006 | RCT# | Intention-to-treat | 1,035/1,019 | 47.6/47.5 | 59.2/60.2 |
Ascione [20] | Italy | March 2004 to December 2006 | RCT, unblinded | Intention-to-treat | 93/93 | 51.3/48.9° | 50.6/58.8° |
Lee [21] | Korea | May 2004 to February 2009 | Controlled | Intention-to-treat | 21/16 | 53.4/53.6° | 64.6/55.3° |
Rumi [22] | Italy | September 2003 to June 2007 | RCT, unblinded | Intention-to-treat | 91/87 | 51.6/52.8° | 60.4/54.8 |